BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Faccioli LA, Dias ML, Paranhos BA, dos Santos Goldenberg RC. Liver cirrhosis: An overview of experimental models in rodents. Life Sciences 2022;301:120615. [DOI: 10.1016/j.lfs.2022.120615] [Reference Citation Analysis]
2 Ioannou P, Karakonstantis S, Schouten J, Kostyanev T, Charani E, Vlahovic-Palcevski V, Kofteridis DP; supported by the ESCMID Study Group for Antimicrobial Stewardship (ESGAP). Indications for medical antibiotic prophylaxis and potential targets for antimicrobial stewardship intervention: a narrative review. Clin Microbiol Infect 2021:S1198-743X(21)00569-3. [PMID: 34653572 DOI: 10.1016/j.cmi.2021.10.001] [Reference Citation Analysis]
3 Zaccherini G, Tufoni M, Iannone G, Caraceni P. Management of Ascites in Patients with Cirrhosis: An Update. J Clin Med 2021;10:5226. [PMID: 34830508 DOI: 10.3390/jcm10225226] [Reference Citation Analysis]
4 Núñez I, Solis-huerta F, Soto-mota A. Serum-ascites albumin gradient – A false dichotomy in the approach to ascites. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.04.010] [Reference Citation Analysis]
5 Haderer M, Neubert P, Rinner E, Scholtis A, Broncy L, Gschwendtner H, Kandulski A, Pavel V, Mehrl A, Brochhausen C, Schlosser S, Gülow K, Kunst C, Müller M. Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases. Gut 2021:gutjnl-2020-321663. [PMID: 33707230 DOI: 10.1136/gutjnl-2020-321663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chaney A. A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis. Clin Exp Gastroenterol 2021;14:385-96. [PMID: 34675586 DOI: 10.2147/CEG.S323778] [Reference Citation Analysis]
7 Flamm SL, Brown K, Wadei HM, Brown RS Jr, Kugelmas M, Samaniego-Picota M, Burra P, Poordad F, Saab S. The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin. Liver Transpl 2021;27:1191-202. [PMID: 33848394 DOI: 10.1002/lt.26072] [Reference Citation Analysis]
8 Ballantine A, Martin D, Thakrar SV. The coagulopathy of liver disease: a shift in thinking. Br J Hosp Med (Lond) 2021;82:1-9. [PMID: 34191571 DOI: 10.12968/hmed.2021.0111] [Reference Citation Analysis]
9 Siau K, Robson N, Bollipo S; Global Online Alliance for Liver Studies (GOAL)., Global Online Alliance for Liver Studies (GOAL). Where should ascitic drains be placed? Revisiting anatomical landmarks for paracentesis. Gut 2021:gutjnl-2020-323731. [PMID: 33402414 DOI: 10.1136/gutjnl-2020-323731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cooper M, Pollard A, Pandey A, Bremner S, Macken L, Evans CJ, Austin M, Parnell N, Steer S, Thomson S, Hashim A, Mason L, Verma S. Palliative Long-Term Abdominal Drains Versus Large Volume Paracentesis in Refractory Ascites Due to Cirrhosis (REDUCe Study): Qualitative Outcomes. J Pain Symptom Manage 2021;62:312-325.e2. [PMID: 33348031 DOI: 10.1016/j.jpainsymman.2020.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Azoulay D, Feray C, Lim C, Salloum C, Conticchio M, Cherqui D, Sa Cunha A, Adam R, Vibert E, Samuel D, Allard MA, Golse N. A systematic review of auxiliary liver transplantation of small for size grafts in patients with chronic liver disease. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100447] [Reference Citation Analysis]
12 Porcel JM, Light RW. Pleural Fluid Analysis: Are Light's Criteria Still Relevant After Half a Century? Clin Chest Med 2021;42:599-609. [PMID: 34774168 DOI: 10.1016/j.ccm.2021.07.003] [Reference Citation Analysis]
13 Mani I, Vrioni G, Hadziyannis E, Alexopoulos T, Vasilieva L, Tsiriga A, Tsiamis C, Tsakris A, Dourakis SP, Alexopoulou A. Bacterial DNA is a prognostic factor for mortality in patients who recover from spontaneous bacterial peritonitis. Ann Gastroenterol 2021;34:852-61. [PMID: 34815652 DOI: 10.20524/aog.2021.0665] [Reference Citation Analysis]
14 Cardoso CC, Matiollo C, Pereira CHJ, Fonseca JS, Alves HEL, Silva OMD, Menegassi VS, Schiavon LL, Santos-Silva MC. B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis. Clin Res Hepatol Gastroenterol 2021;45:101698. [PMID: 33852953 DOI: 10.1016/j.clinre.2021.101698] [Reference Citation Analysis]
15 Palaniyappan N, Aithal GP. Midodrine and the Ladder of Evidence to Climb. J Clin Exp Hepatol 2021;11:528-30. [PMID: 34511812 DOI: 10.1016/j.jceh.2021.07.002] [Reference Citation Analysis]
16 Yang L, Liu S, Zhang Q, Jia S, Qiu C, Jin Z. Overexpression of ascitic interleukin-35 induces CD8+ T cell exhaustion in liver cirrhotic patients with spontaneous bacterial peritonitis. Int Immunopharmacol 2022;108:108729. [PMID: 35349961 DOI: 10.1016/j.intimp.2022.108729] [Reference Citation Analysis]
17 Mattock R, Tripathi D, O'Neill F, Craig J, Tanner J, Patch D, Aithal G. Economic evaluation of covered stents for transjugular intrahepatic portosystemic stent shunt in patients with variceal bleeding and refractory ascites secondary to cirrhosis. BMJ Open Gastroenterol 2021;8:e000641. [PMID: 34429322 DOI: 10.1136/bmjgast-2021-000641] [Reference Citation Analysis]
18 Ay Y, Canakci ME, Temel T, Ozakin E, Acar N. Hemodynamic Instability in Emergency Department: Giant Rectus Sheath Hematoma and Point-of-Care Ultrasonography. Cureus 2021;13:e13669. [PMID: 33824820 DOI: 10.7759/cureus.13669] [Reference Citation Analysis]
19 Qi X, Bai Z, Zhu Q, Cheng G, Chen Y, Dang X, Ding H, Han J, Han L, He Y, Ji F, Jin H, Li B, Li H, Li Y, Li Z, Liu B, Liu F, Liu L, Lin S, Ma D, Meng F, Qi R, Ren T, Shao L, Tang S, Tang Y, Teng Y, Wang C, Wang R, Wu Y, Xu X, Yang L, Yuan J, Yuan S, Yang Y, Zhao Q, Zhang W, Yang Y, Guo X, Xie W. Practice guidance for the use of terlipressin for liver cirrhosis–related complications. Therap Adv Gastroenterol 2022;15:175628482210982. [DOI: 10.1177/17562848221098253] [Reference Citation Analysis]
20 Taguchi K, Okamoto Y, Matsumoto K, Otagiri M, Chuang VTG. When Albumin Meets Liposomes: A Feasible Drug Carrier for Biomedical Applications. Pharmaceuticals (Basel) 2021;14:296. [PMID: 33810483 DOI: 10.3390/ph14040296] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Erstad BL. Albumin for cirrhosis-related complications. J Clin Pharm Ther 2021;46:887-94. [PMID: 34101215 DOI: 10.1111/jcpt.13461] [Reference Citation Analysis]
22 Baiges A, Hernández-Gea V. Management of Liver Decompensation in Advanced Chronic Liver Disease: Ascites, Hyponatremia, and Gastroesophageal Variceal Bleeding. Clin Drug Investig 2022. [PMID: 35476218 DOI: 10.1007/s40261-022-01147-5] [Reference Citation Analysis]
23 Orman ES, Johnson AW, Ghabril M, Sachs GA. Hospice care for end stage liver disease in the United States. Expert Rev Gastroenterol Hepatol 2021;15:797-809. [PMID: 33599185 DOI: 10.1080/17474124.2021.1892487] [Reference Citation Analysis]
24 Macken L, Palaniyappan N, Verma S, Aithal G. Large volume paracentesis: to do or where to do? Gut 2021:gutjnl-2021-324249. [PMID: 33712436 DOI: 10.1136/gutjnl-2021-324249] [Reference Citation Analysis]
25 Jackson K, Davidson R, Aujayeb A. Hepatic hydrothorax in the management of cirrhosis. Gut 2021:gutjnl-2021-324698. [PMID: 33789969 DOI: 10.1136/gutjnl-2021-324698] [Reference Citation Analysis]
26 Zhang B, Cai W, Gao F, Lin X, Qian T, Gu K, Song B, Chen T. Prediction of Patient Survival with Psoas Muscle Density Following Transjugular Intrahepatic Portosystemic Shunts: A Retrospective Cohort Study. Med Sci Monit 2022;28:e934057. [PMID: 35031594 DOI: 10.12659/MSM.934057] [Reference Citation Analysis]
27 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacol Res 2022;181:106261. [PMID: 35588918 DOI: 10.1016/j.phrs.2022.106261] [Reference Citation Analysis]
28 Adachi T, Takeuchi Y, Takaki A, Oyama A, Wada N, Onishi H, Shiraha H, Okada H. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. Int J Mol Sci 2021;22:5582. [PMID: 34070416 DOI: 10.3390/ijms22115582] [Reference Citation Analysis]
29 Téllez L, Rodríguez de Santiago E, Albillos A. Fontan-Associated Liver Disease: Pathophysiology, Staging, and Management. Semin Liver Dis 2021. [PMID: 34399435 DOI: 10.1055/s-0041-1732355] [Reference Citation Analysis]